Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of...

Full description

Bibliographic Details

Published in:	Cancer cell Vol. 28; no. 1; p. 11
Main Authors:	Kelderman, Sander, Schumacher, Ton N, Kvistborg, Pia
Format:	Journal Article
Language:	English
Published:	United States 13.07.2015
Subjects:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use DNA Mismatch Repair Humans Neoplasms - drug therapy Neoplasms - metabolism Programmed Cell Death 1 Receptor - antagonists & inhibitors Tumor Microenvironment - drug effects
ISSN:	1878-3686, 1878-3686
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!